PACAREG: A Multicenter Registry Trial In Pancreatic Ductal Adencarcinoma

Study Overview

PACAREG: a Multicenter Registry Trial in Pancreatic Ductal Adencarcinoma

PaCaReg is a multicenter registry trial aiming in the assessement of clinical, epidemiological and biological profiles in patients with pancreatic ductal adenocarcinoma

N/A

Pancreas Adenocarcinoma
Pancreas Cancer

PaCaReg

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2019-09-18	Results First Submitted N/A	Last Update Submitted that met QC Criteria 2019-09-23
First Submitted that Met QC Criteria 2019-09-18	Results First Submitted that Met QC Criteria N/A	Last Update Posted (ACTUAL) 2019-09-25
First Posted (ACTUAL) 2019-09-23	Results First Posted N/A	Last Verified 2019-09

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
N/A

Allocation:
N/A

Interventional Model:
N/A

Masking:
N/A

Arms and Interventions

Participant Group/Arm	Intervention/Treatment

Primary Outcome Measures	Measure Description	Time Frame
General assessment of applied therapy modalities in pancreatic cancer		First diagnose to death or end of surveillance (5 years after curative resection)
Quality of life in pancreatic cancer patients	EORTC QLQ c30 and PAN 26	First diagnose to death or end of surveillance (5 years after curative resection)

Secondary Outcome Measures	Measure Description	Time Frame
General epidemiologic assessment	Epidemiologic questionaire	First diagnose to death or end of surveillance (5 years after curative resection)
Assessment of tumor surveillance in pancreatic cancer patients		First diagnose to death or end of surveillance (5 years after curative resection)
Evaluation of predictive and prognostic markers		First diagnose to death or end of surveillance (5 years after curative resection)

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Thomas Seufferlein, MD

Phone Number: +49 731 50044501

Email: thomas.seufferlein@uniklinik-ulm.de

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

Treatment naive histologically or cytologically proven pancreatic ductal adenocarcinoma (PDAC) or highly suspicious diagnosis (only pre-curative-intended resection)
Age =>18 years
written informed consent

papillary cancer
neuroendocrine pancreatic tumors

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

PRINCIPAL_INVESTIGATOR: Thomas Seufferlein, MD, Ulm University Hospital

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Learn

Resources

PatientS

Caregivers

Clinical Trial Record